1. 42PPrediction of PFS using a dynamic assessment of ctDNA in patients with EGFR mutated NSCLC with osimertinib therapy. (7th November 2019) Authors: Moiseenko, F; Stepanova, M; Zhabina, A; Myslik, A; Klimenko, V; Rysev, N; Artemieva, E; Shelekhova, K; Bogdanov, A; Volkov, N; Moiseenko, V Journal: Annals of oncology Issue: Volume 30(2019)Supplement 7 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 54PInvestigation of the mechanisms of resistance to osimertinib in patients with T790M-associated NSCLC. (7th November 2019) Authors: Stepanova, M; Moiseenko, F; Zhabina, A; Klimenko, V; Rysev, N; Myslik, A; Artemieva, E; Shelekhova, K; Bogdanov, A; Volkov, N; Moiseenko, V Journal: Annals of oncology Issue: Volume 30(2019)Supplement 7 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 75PDynamics of ctDNA in patients with NSCLC. (7th November 2019) Authors: Zhabina, A S; Mjslik, A; Moiseenko, F; Moiseenko, V; Stepanova, M Journal: Annals of oncology Issue: Volume 30(2019)Supplement 7 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. O-022Phase II study evaluating trifluridine/tipiracil + bevacizumab and capecitabine + bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are non-eligible for intensive therapy (TASCO1): Results of the primary analysis. (20th June 2018) Authors: Lesniewski-Kmak, K; Moiseenko, V; Saunders, M; Wasan, H; Argiles, G; Borg, C; Creemers, G; Fedyanin, M; Glynne-Jones, R; Pfeiffer, P; Punt, C; Stroyakovskiy, D; Ten Tije, A; Van de Wouw, A; Kanehisa, A; Fougeray, R; Busto, N Lopez; Amellal, N; Van Cutsem, E Journal: Annals of oncology Issue: Volume 29(2018)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. O-022Phase II study evaluating trifluridine/tipiracil + bevacizumab and capecitabine + bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are non-eligible for intensive therapy (TASCO1): Results of the primary analysis. (20th June 2018) Authors: Lesniewski-Kmak, K; Moiseenko, V; Saunders, M; Wasan, H; Argiles, G; Borg, C; Creemers, G; Fedyanin, M; Glynne-Jones, R; Pfeiffer, P; Punt, C; Stroyakovskiy, D; Ten Tije, A; Van de Wouw, A; Kanehisa, A; Fougeray, R; Busto, N Lopez; Amellal, N; Van Cutsem, E Journal: Annals of oncology Issue: Volume 29(2018)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P-058Trifluridine/tipiracil safety and efficacy in Russian patients with metastatic colorectal cancer and refractory or intolerant to standard chemotherapies: Results of the primary analysis. (2nd July 2019) Authors: Fedyanin, M; Chekini, D; Chubenko, V; Tjulandin, S; Zhabina, A; Amellal, N; Aubel, P; Gandossi, E; Moiseenko, V Journal: Annals of oncology Issue: Volume 30(2019)Supplement 4 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. RF plasma simulations using the TOMATOR 1D code: a case study for TCV helium ECRH plasmas. (20th August 2020) Authors: Wauters, T; Buermans, J; Haelterman, R; Moiseenko, V; Ricci, D; Verhaeghe, T; Coda, S; Douai, D; Hakola, A; Lyssoivan, A; Van Eester, D Other Names: collab.; collab. Journal: Plasma physics and controlled fusion Issue: Volume 62:Number 10(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗